Biogen Inc.: Health Canada Grants Authorization for LEQEMBI
Biogen Inc. and Eisai Co., Ltd. announced that Health Canada has issued a Notice of Compliance with Conditions for LEQEMBI (lecanemab) for the treatment of early Alzheimer's disease.
LEQEMBI is a humanized anti-soluble aggregated amyloid-beta (Aß) monoclonal antibody for adult patients with mild cognitive impairment or mild dementia due to Alzheimer's disease.
The treatment is intended for patients who are apolipoprotein E e4 (ApoE e4*) non-carriers or heterozygotes and have confirmed amyloid pathology.
LEQEMBI is the first treatment for early AD that targets an underlying cause of the disease to be authorized in Canada.
No additional quotes are available in the text.
Author's summary: Biogen Inc. receives Health Canada authorization for LEQEMBI.
More News
- Budget jitters see construction forecasts plummet
- The environmental impact of the 2026 World Cup
- Three resilient UK multinationals global managers are excited about | Trustnet
- Sweden’s still ahead in the preparedness game — and now it means business
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Battlefield 6's Battle Royale Mode Is Called REDSEC, Is Free-To-Play, And Launches Tomorrow
- Renters Rights Bill becomes law - Letting Agent Today
- 2 US Navy aircraft crash in South China Sea
- Family office conflicts surge as wealthy clans grapple with two major challenges
- Pirates Listed as Potential Fit for Trent Grisham, Luis Arráez and Other Top Free Agents